Phase II trial of intensity-modulated radiotherapy concurrent with chemotherapy in patients with node-positive esophageal cancer after radical surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-10001140

Enrollment

Unknown

Registered

2010-12-21

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

A:Intensity-Modulated Radiotherapy with Concurrent Weekly Docetaxel 20 mg/m2 for 5 Weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years old. 2. Informed consent was obtained. 3. R0 resection had received at the radical surgery, and histological confirmation of esophageal cancer with node-positive. 4. Karnofsky performance status not less than 70. 5. Appropriate haematological, hepatic and renal function.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients. 2. Serious complications (severe heart disease and tendency to bleeding). 3. Previous treatment with radiotherapy or chemotherapy. 4. Distant metastases or local recurrences.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactJincheng Lu

lujincheng@msn.com+86 25 83284632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026